# A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism

> **NCT01653379** · PHASE2 · COMPLETED · sponsor: **Deltanoid Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** DP001

## Key facts

- **NCT ID:** NCT01653379
- **Lead sponsor:** Deltanoid Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01653379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01653379, "A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01653379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*